QTV-23573-59308
3 vaccinations
4 coded responses
21 check-ins
4 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 46-50
- ZIP prefix
- 751 / TX
- Registered
- 2020-12-28
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-28
Registered in v-safe
-
2020-12-28
Dose 1 — Pfizer-BioNTech
- 2020-12-28
- 2020-12-29
- 2020-12-30
-
2020-12-31
Survey response — days 1–6 daily, dose 1MedDRA: Dyspnoea exertional — Feeling: Good · Fatigue or tirednessFree text: A little short of breath with exertionMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-01-01
-
2021-01-02
Health check-in — days 1–6 daily, dose 1Feeling: Good · Joint pains, Muscle or body achesAdult check-in
- 2021-01-06
-
2021-01-18
Dose 2 — Pfizer-BioNTech
- 2021-01-19
-
2021-01-20
Survey response — days 1–6 daily, dose 2MedDRA: Adverse reaction, Symptom recurrence — Feeling: Good · Site: Pain · Joint pains, Muscle or body aches, Fatigue or tirednessFree text: These symptoms started at 10pm last night were gone by 2pm todayMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-01-21
- 2021-01-24
- 2021-01-25
- 2021-02-01
- 2021-02-08
- 2021-02-15
- 2021-02-22
- 2021-03-01
- 2021-04-19
- 2021-07-21
-
2021-10-08
Dose 3 — Pfizer-BioNTech
-
2022-01-18
Survey response — 12 months, dose 2MedDRA: Back pain, Cough, Dry mouth, Dyspnoea, Epistaxis, Headache, Night sweats, Respiratory tract congestion — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Headache, back pain, night sweats, nose bleeds, shortness of breath, cough, congestion, severe dry mouth,MedDRA releases: 2024-11 · check-in free text available
-
2022-01-18
Report sent to call center — 12 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2022-01-19
- 2022-01-24
-
2022-04-08
Survey response — 6 months, dose 3MedDRA: Gastric operation — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · HospitalizationFree text: Gastric surgeryMedDRA releases: 2024-11 · check-in free text available
-
2022-04-08
Report sent to call center — 6 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prHospitalization · 1 call case(s)
- 2022-04-12
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-28 | Pfizer-BioNTech | |
| 2 | 2021-01-18 | Pfizer-BioNTech | |
| 3 | 2021-10-08 | Pfizer-BioNTech | No |
Call center
2 call center cases
2 unsuccessful
Free text
Release 1 — days 1–6 daily, dose 1
Systemic reaction (other): A little short of breath with exertion
Release 2 — days 1–6 daily, dose 2
Systemic reaction (other): These symptoms started at 10pm last night were gone by 2pm today
Release 10 — 12 months, dose 2
Symptoms: Headache, back pain, night sweats, nose bleeds, shortness of breath, cough, congestion, severe dry mouth,
Release 11 — 6 months, dose 3
Symptoms: Gastric surgery
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Back pain | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | Dry mouth | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Epistaxis | · | · | ✓ |
| SD | Gastric operation | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Night sweats | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SRO | Adverse reaction | ✓ | · | ✓ |
| SRO | Dyspnoea | ○ | ○ | ○ |
| SRO | Dyspnoea exertional | ✓ | ✓ | ✓ |
| SRO | Symptom recurrence | ○ | ✓ | ○ |
✓ active code · ○ coded but marked inactive · blank = not in that release